ProAssurance (PRA) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
15 Jan, 2026Executive summary
Reported net income of $16.4 million and operating income of $17.3 million for Q3 2024, reversing a significant loss in Q3 2023.
Book value per share increased to $24.07 at September 30, 2024, up from $21.82 at year-end 2023, supported by net income and after-tax unrealized holding gains.
Return on equity improved to 5.6% for Q3 2024; non-GAAP operating ROE was 5.9%.
Nine-month operating earnings reached $0.64 per share, reflecting ongoing progress toward long-term profitability objectives.
Consolidated net premiums earned were $243.2 million for Q3 2024, nearly flat year-over-year.
Financial highlights
Net investment income rose 13.8% year-over-year to $37.3 million in Q3 2024; new purchase yields at 5.2%, 160 basis points above the average book yield.
Combined ratio improved to 105.6% in Q3 2024 from 116.7% in Q3 2023; specialty P&C combined ratio was 99.5%.
Net favorable prior year reserve development of $21.8 million in Q3 2024, especially from older accident years and the NORCAL book.
Book value per share increased by over $2 since year-end to $24.07; adjusted book value per share at $26.52.
Net income swung to $16.4 million from a loss of $49.4 million in Q3 2023.
Outlook and guidance
Management expects continued improvement in underwriting results due to ongoing pricing and underwriting actions, especially in the MPL line.
Investment income is anticipated to benefit from higher yields as the portfolio matures.
No significant increase in expense ratio anticipated for Q4; no material changes to risk factors or forward-looking statements since the last annual report.
Latest events from ProAssurance
- 2025 net income reached $50.9M, with improved ratios and a pending merger expected to close in 2026.PRA
Q4 202523 Feb 2026 - Net income rose 45.9% to $15.5M as investment income surged and NORCAL gain was recognized.PRA
Q2 20241 Feb 2026 - Operating and net income rose, with higher book value and strong investment returns.PRA
Q4 202423 Dec 2025 - Shareholders to vote on $25.00/share cash merger, board recommends approval, closing expected 2026.PRA
Proxy Filing1 Dec 2025 - Director elections, auditor ratification, and say-on-pay highlight a performance-driven, well-governed agenda.PRA
Proxy Filing1 Dec 2025 - Shareholders to vote on $25.00 per share cash merger; board unanimously recommends approval.PRA
Proxy Filing1 Dec 2025 - ProAssurance to be acquired by The Doctors Company in a $1.3B deal, closing first half 2026.PRA
Proxy Filing1 Dec 2025 - Acquisition will create the largest physician-owned medical malpractice insurer, pending approvals.PRA
Proxy Filing1 Dec 2025 - Acquisition by The Doctors Company advances, with key votes and regulatory steps outlined.PRA
Proxy Filing1 Dec 2025